Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00713401 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Tecadenoson to Treat Atrial Fibrillation
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00713401 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 21 participants.
The verdict
NCT00713401, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
Assess the tolerability and safety of a rapid bolus of tecadenoson at different dose levels when given alone and in combination with a beta-blocker (esmolol) in patients with atrial fibrillation to control rapid heart rate. Explore the pharmacokinetic and pharmacodynamic effects when given alone and in combination with beta-blocker (esmolol).
Interventions
- DRUG Esmolol
- DRUG Tecadenoson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00713401
The ClinicalTrials.gov registry entry for NCT00713401 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Esmolol is the first listed.
NCT00713401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00713401 about?
NCT00713401 is a clinical study titled "Safety Study of Tecadenoson to Treat Atrial Fibrillation". Assess the tolerability and safety of a rapid bolus of tecadenoson at different dose levels when given alone and in combination with a beta-blocker (esmolol) in patients with atrial fibrillation to control rapid heart rate. Explore the pharmacokinetic and pharmacodynamic effects when given alone and...
What is the current status of trial NCT00713401?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2008-02. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00713401?
The interventions under investigation include: Esmolol (DRUG), Tecadenoson (DRUG).
Who is sponsoring clinical trial NCT00713401?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.